One drug. One target. A lot riding on it.
In the spring of 2026, a letter from the FDA changed the temperature inside a modest office on Market Street. Plixorafenib - the only drug Fore Biotherapeutics is developing - had been granted Breakthrough Therapy Designation for BRAF V600E-mutated high-grade glioma. The company believes it is the first such designation ever handed to a targeted therapy for that brutal class of brain tumor.
Fore is not a sprawling pipeline company. It is a focused bet, made by about 55 people, on the idea that one well-aimed molecule beats a dozen scattershot ones.
That is an unfashionable way to run a biotech. Most companies hedge. Fore concentrated. The whole enterprise - $204.5M in funding, a board stacked with life-sciences heavyweights, years of clinical work - points at a single pathway in cancer biology. If plixorafenib works, the focus looks like genius. If it doesn't, there is no plan B sitting on a shelf.
“A registration-stage targeted oncology company dedicated to developing new treatments that provide better outcomes for patients with the hardest-to-treat cancers.”
BRAF is a famous villain. It's also a slippery one.
BRAF is one of the most-studied genes in cancer. Mutate it, and cells grow when they shouldn't. The pharmaceutical industry has answered with a generation of BRAF inhibitors, and for some tumors - melanoma, most famously - they work well.
The trouble is what they don't reach. Many BRAF-altered cancers shrug off the first wave of inhibitors. Brain tumors are worse still: the drug has to cross into the central nervous system, and most molecules simply can't get there in useful amounts. So patients with BRAF V600E high-grade glioma have had, in practical terms, no targeted option at all. Just the old, blunt instruments.
That gap - a known target with no drug that can actually hit it where it lives - is the tension the entire company exists to resolve.
BRAF V600E high-grade glioma had no targeted therapy. The mutation was visible for years. The medicine just couldn't get to it.
From reading mutations to drugging them
Fore did not start as a drug company. It started in 2011 in Israel as NovellusDx, a functional-genomics outfit that sold a way to read what tumor mutations actually do - useful intelligence for pharma, but not a medicine itself.
Around 2019, under then-CEO Michael Vidne, the team noticed something. The platform built to characterize mutations was, in effect, a map of drug-development opportunities. So they made the harder choice: stop selling the map, and go build the medicine. NovellusDx became Fore Biotherapeutics, traded Tel Aviv diagnostics for Philadelphia therapeutics, and pointed everything at BRAF.
The people steering it
Today the company is led by CEO William Hinshaw, with a clinical and corporate bench drawn from larger oncology shops, and a board that reads like a who's who of life-sciences venture capital.
Pictured in spirit: a board that has collectively shepherded more drugs to market than most countries, now focused on a single one.
Plixorafenib, the “dimer breaker”
BRAF proteins often work in pairs - dimers - and that pairing is one way tumors slip past older inhibitors. Plixorafenib is designed as a dimer breaker: highly selective, built to disrupt that pairing across both Class I/V600 and Class II BRAF alterations, and engineered to actually reach tumors in the central nervous system.
Plixorafenib (FORE8394)
A next-generation, highly selective BRAF inhibitor targeting BRAF-altered solid tumors, including BRAF V600E high-grade glioma and other primary CNS tumors. Granted FDA Breakthrough Therapy Designation in April 2026.
The FORTE trial
A Phase 2 basket study evaluating plixorafenib monotherapy in recurrent or progressive BRAF V600 primary CNS tumors and other BRAF-altered cancers. Topline CNS results are expected by the end of 2026 - the data that could trigger an FDA filing.
“We want patients to spend less time thinking about cancer and more time enjoying life.”
How a diagnostics lab became a cancer-drug contender
An Israeli functional-genomics startup selling insight into tumor mutations.
Leadership recognizes the platform points to drug opportunities; the shift to therapeutics begins.
Rebrands and relocates focus to Philadelphia precision oncology, with plixorafenib as lead asset.
Major financing alongside a CEO transition to accelerate the program.
Extension round to expedite plixorafenib, backed by a global investor syndicate.
Granted for BRAF V600E high-grade glioma - believed to be a first for a targeted therapy in HGG.
The numbers behind the bet
Conviction is cheap in biotech. Data is not. The early Phase 1/2a results gave the company something to point at: in a pre-specified subgroup of MAPK-inhibitor-naive patients with BRAF V600-mutated primary CNS tumors, plixorafenib produced a 67% overall response rate, with responses that lasted.
Funding momentum
Investors include SR One, Medicxi, OrbiMed, HBM Healthcare Investments, Wellington Management, Novartis Venture Fund, Cormorant Asset Management and 3B Future Health Fund. Prior-round figure is approximate. Bars scaled for comparison.
$204.5M, eight named investors, one molecule. Focus, it turns out, is also a form of risk.
Patient first, and they mean the order literally
Fore organizes itself around five stated values - Patient First, Science, Focus, Excellence, Compassion - and the ordering is not accidental. The science exists to serve the patient, not the other way around. It is the kind of line every biotech puts in a deck; the difference here is that the company's entire structure, a single asset aimed at people with no other targeted option, makes the claim hard to fake.
The investor syndicate reads like an endorsement of that focus. SR One, OrbiMed and Medicxi have backed the company for years; Novartis Venture Fund and Wellington Management joined the later rounds. Regulators, for their part, signaled their own interest by granting Breakthrough Therapy status - a designation meant to speed exactly this kind of drug toward patients faster.
The letter on Market Street was just the opening
Breakthrough Therapy Designation is a vote of confidence, not an approval. The real test arrives at the end of 2026, when topline results from the FORTE basket are due. If they hold up, Fore believes the data could support a New Drug Application under the FDA's accelerated approval pathway - which is to say, a path from lab to clinic to pharmacy.
Go back to that spring morning in Philadelphia. A 55-person company opens a letter that says, in the FDA's careful language, that their one drug might matter.
For patients with BRAF V600E high-grade glioma, “might” is more than they had the day before. That is what Fore Biotherapeutics changed: not the diagnosis, not yet the outcome, but the odds that someone, somewhere, was finally building the medicine the mutation always demanded. The next chapter gets written in the trial data - and everyone in that building knows it.